Department of Radiology, Hanyang University College of Medicine, Seongdong-gu, South Korea.
Department of Internal Medicine, Hanyang University College of Medicine, Seongdong-gu, South Korea.
Liver Int. 2022 Jul;42(7):1536-1544. doi: 10.1111/liv.15259. Epub 2022 Apr 12.
BACKGROUND & AIMS: There are several reports on the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD). However, the prevalence of advanced hepatic fibrosis in MAFLD is largely unknown. We aimed to evaluate the prevalence of advanced fibrosis in MAFLD.
A total of 6775 subjects from nationwide 13 health check-up centres were included in this cross-sectional study. Fatty liver was evaluated using ultrasonography. Significant (≥F2) and advanced (≥F3) hepatic fibrosis were defined by MRE thresholds of 3.0 kPa (range: 2.99-3.65 kPa) and 3.6 kPa (range: 3.4-3.9 kPa) respectively. The sex- and age-standardized prevalence of MAFLD and hepatic fibrosis was estimated.
The sex- and age-standardized prevalence of MAFLD was 33.9%. The prevalence of obesity (BMI ≥25 kg/m ) in MAFLD was 71.1%, and 79.0% of obese subjects had MAFLD. The prevalence of diabetes in MAFLD was 13.3%, and 73.6% of subjects with diabetes had MAFLD. The sex- and age-standardized prevalence of significant (≥F2) and advanced hepatic fibrosis (≥F3) amongst MAFLD was 9.7% (range: 3.0-9.8%) and 3.0% (range: 2.6-4.6%) respectively. The prevalence of advanced hepatic fibrosis in overweight/obese (group I), lean (group II) and diabetic (group III) MAFLD was 2.3%, 3.1% and 9.5% respectively.
The sex- and age-standardized prevalence of advanced fibrosis was 3.0% (range: 2.6-4.6%) in subjects with MAFLD.
有几项关于代谢功能相关脂肪性肝病（MAFLD）流行率的报告。然而，MAFLD 中晚期肝纤维化的流行率在很大程度上尚不清楚。本研究旨在评估 MAFLD 中晚期纤维化的流行率。
本横断面研究共纳入来自全国 13 个健康体检中心的 6775 例受试者。使用超声检查评估脂肪肝。通过 MRE 阈值（范围：2.99-3.65kPa）定义显著（≥F2）和晚期（≥F3）肝纤维化，分别为 3.0kPa（范围：2.99-3.65kPa）和 3.6kPa（范围：3.4-3.9kPa）。估计 MAFLD 和肝纤维化的性别和年龄标准化流行率。
性别和年龄标准化的 MAFLD 流行率为 33.9%。MAFLD 中肥胖（BMI≥25kg/m ）的流行率为 71.1%，肥胖患者中有 79.0%患有 MAFLD。MAFLD 中糖尿病的流行率为 13.3%，糖尿病患者中有 73.6%患有 MAFLD。MAFLD 中显著（≥F2）和晚期（≥F3）肝纤维化的性别和年龄标准化流行率分别为 9.7%（范围：3.0-9.8%）和 3.0%（范围：2.6-4.6%）。超重/肥胖（I 组）、偏瘦（II 组）和糖尿病（III 组）MAFLD 患者中晚期肝纤维化的流行率分别为 2.3%、3.1%和 9.5%。
MAFLD 患者中晚期纤维化的性别和年龄标准化流行率为 3.0%（范围：2.6-4.6%）。
